Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study

Table 1 Summary of the prognostic scoring systems (points)

Prognostic system	Constituents		Risk stratification		Candidates
HAP	Albumin < 36 g/L	1	HAP A	0	Yes
	AFP > 400 ng/mL	1	HAP B	1
	Tumor diameter > 7 cm	1	HAP C	2	No
	Bilirubin > 17 μmol/L	1	HAP D	3-4
mHAP	Albumin < 36 g/L	1	mHAP A	0	Yes
	AFP > 400 ng/dL	1	mHAP B	1
	Tumor diameter > 7 cm	1	mHAP C	2	No
			mHAP D	3
mHAP2	Albumin < 36 g/L	1	mHAP2 A	0	Yes
	AFP > 400 ng/mL	1	mHAP2 B	1
	Tumor diameter > 7 cm	1	mHAP2 C	2	No
	Tumor number ≥ 2	1	mHAP2 D	3-5
	Bilirubin > 0.9 mg/dL	1
mHAP3	The prognostic index (PI) formula: (0.104 × size in cm) + [0.3089 × number (single nodule = 1; 2-3 nodules = 2; more than three nodules = 3)] + (0.2185 × Log10AFP in ng/mL) - (0.4049 × Albumin in g/dL) + (0.1506 × Bilirubin in mg/dL)		< Median PI		Yes
			≥ Median PI		No
6&12	Score = Tumor size in cm + Tumor number		< Median Score		Yes
			≥ Median Score		No
ART	Absence of radiologic response	1	0-1.5		Yes
	AST increase >25 %	4
	Child-Pugh increase: 1 point	1.5	≥ 2.5		No
	≥ 2 points	3
ABCR	Presence of radiologic response	-3	≤ 2		Yes
	AFP ≥ 200 ng/mL	1
	BCLC B	2
	BCLC C	3	≥ 3		No
	Child-Pugh increase: ≥ 2 points	2

BCLC: Barcelona Clinic Liver Cancer; HAP: Hepatoma Arterial-embolization Prognostic; mHAP: Modified HAP; 6&12: Six-and-twelve criteria; ART: Assessment for re-treatment with TACE; ABCR: Alpha-fetoprotein, BCLC stage, Child-Pugh and Response.